Waters Corporation (WAT) Business Profile

What it does

Waters Corporation makes laboratory instruments, software and supplies used to analyze materials and biological samples. Its customers include drug developers, clinical laboratories, industrial companies, universities and government agencies. Founded in 1958, Waters is headquartered in Milford. Udit Batra is its president and chief executive officer.

A core technology is liquid chromatography, which separates a sample into its components so a laboratory can identify and measure them. Waters also sells mass spectrometers, which help identify and quantify compounds. Laboratories often use the two technologies together, for example in drug development, food safety and environmental testing. Waters sells the instruments alongside software, replaceable columns, other supplies and service plans.

The company also makes thermal analysis, rheometry and calorimetry instruments through its TA product line. These measure properties such as how a material responds to temperature or flows under pressure. Customers use them to study materials ranging from pharmaceuticals to polymers and metals.

In February 2026, Waters acquired Becton, Dickinson and Company’s Biosciences and Diagnostic Solutions businesses. The acquired portfolio includes products for collecting and transporting diagnostic specimens, infectious-disease and cancer testing, and flow cytometry instruments and reagents used in research and clinical diagnostics. Waters has organized its businesses into Analytical Sciences, Biosciences, Advanced Diagnostics and Materials Sciences.

How it makes money

In 2025, Waters’ net sales increased 7%; in Q3 2026, total company revenue was $1.767 billion.

Waters earns revenue when it sells instruments and as customers use and maintain them. Its chromatography and mass spectrometry systems can be sold together with common software. Chromatography columns contain material that separates a sample and are typically replaced at regular intervals. Waters also sells other precision chemistry consumables, including products used for laboratory quality control and proficiency testing.

Service revenue comes from support plans, on-demand repairs, spare parts, performance validation and training. A support plan typically covers scheduled maintenance and prompt repairs for a contractual fee based on the instrument’s configuration. The TA business similarly earns service revenue from support plans, replacement parts and labor to repair, maintain or upgrade installed systems.

For FY2025, Waters Instrument Systems and Waters Service each generated $1.1 billion in revenue. Chemistry consumables generated $631.5 million. The acquired Biosciences and Diagnostic Solutions businesses were not included in Waters’ 2025 consolidated results, so those figures do not describe the full company after the acquisition.

Waters has also been moving its Empower software toward a subscription model. The company is offering AI-enabled features in a premium subscription tier and expects the Empower subscription transition to become neutral to growth in 2027. For the acquired businesses, Waters is working on pricing and reagent-rental contract compliance as sources of revenue.

Customers and how it sells

Pharmaceutical accounts represented 59.0% of Waters’ FY2025 revenue. They include multinational drug companies, generic manufacturers, biotechnology companies and contract research organizations. Other customers include chemical and polymer manufacturers, food and beverage companies, environmental laboratories, universities and government agencies. No single customer accounted for more than 2% of net sales in 2025.

Waters sells and supports its products through a direct field organization. Sales representatives manage customer relationships, while service staff install instruments, train users and help reduce downtime. Consumables are also available through electronic ordering and a catalog. Instrument purchases depend in part on customers’ capital budgets and, for research institutions, available funding.

In FY2025, the United States accounted for 30.5% of revenue, Europe 30.4%, Asia Other 19.0% and China 13.8%. Those figures predate the Biosciences and Diagnostic Solutions acquisition. In Q3 2026, Waters reported revenue of $749 million in the Americas, $523 million in Europe and $495 million in Asia.

Waters also has commercial partnerships with Quest Diagnostics and LabCorp to add its OnClarity HPV self-collection kit to their test menus. The company expects revenue from those partnerships to begin in 2027 as samples are processed.

Suppliers and costs

Waters manufactures in the United States, Ireland and the United Kingdom, and uses subcontractors in Singapore. It processes silica and polymeric resins, packs chromatography columns and distributes those products. Its international manufacturing and sales expose it to tariffs, trade restrictions and possible supply-chain disruptions.

Payroll, transaction and integration work, and systems implementation affect operating costs. Waters recorded approximately $82 million of transaction, integration and other internal costs associated with the Biosciences and Diagnostic Solutions acquisition in 2025, along with $20 million of expenses for its new ERP system implementation. Operating income was $803 million in 2025.

To fund a cash distribution connected with the acquisition, Waters assumed approximately $4.0 billion of new indebtedness. The company expects to refinance the larger term-loan tranche with long-term bond financing and to repay the other tranche before maturity. Waters is also pursuing procurement savings by consolidating spending across its original and acquired businesses.

Competitive position

Waters competes in analytical instruments, supplies and services on product performance, reliability, service and, to a lesser extent, price. Its principal competitors in Waters markets include Agilent Technologies, Shimadzu, Bruker, Danaher and Thermo Fisher Scientific. In consumables, it also names Merck KGaA and General Electric among competitors. Some competitors have broader distribution and greater financial resources than Waters.

TA’s competitors include PerkinElmer, NETZSCH-Geraetebau, Malvern PANalytical, Spectris and Anton-Paar. In the acquired Biosciences and Diagnostic Solutions markets, Waters names Danaher, Revvity, Cytek Biosciences and bioMérieux. Agilent, Revvity and Thermo Fisher can provide some services on Waters instruments.

Our reading: The combination of installed instruments, service relationships and regularly replaced columns gives Waters a meaningful source of repeat business, although customers can also use some Waters columns on competing systems. Our reading: Software integrated into laboratory workflows can make Waters’ products harder to replace, but the evidence does not establish how often customers switch. Our reading: Waters’ ability to process column materials and distribute its own products supports control over consistency, while the fragmented consumables market limits any assumption that manufacturing alone insulates it from competition.

Growth opportunities

Waters is expanding beyond its original analytical instrument portfolio through the acquired Biosciences and Diagnostic Solutions businesses. Its growth plans include new flow cytometry instruments, diagnostic products, service-plan attachment and digital sales channels. The company expects to deliver $50 million of revenue synergies in 2026 from the combination.

Waters expects its OnClarity HPV self-collection kit and partnerships with Quest Diagnostics and LabCorp to expand access to testing. It has also launched a China localization initiative for its microbiology portfolio and expects that effort to support future growth. In Biosciences, local manufacturing in China came online ahead of schedule.

In its original business, Waters is pursuing demand from instrument replacement, biologics, pharmaceutical manufacturing investment and laboratory automation. The company has received double-digit millions of dollars in orders tied to new pharmaceutical sites. It estimates that the semiconductor and data-center testing market it serves across two divisions is approximately $600 million.

Waters is adding AI features to Empower through a premium subscription tier. It says a pilot of AI-powered peak integration at a pharmaceutical customer reduced manual interventions by up to 95%. It was reported on 3 November 2026 that Waters had acquired MOBILion Systems, which develops high-resolution ion mobility separation technology. Waters sizes the discovery proteomics market at $2.2 billion and plans to pair the acquired separation technology with its Xevo MRT mass spectrometer.

Structural risks

• Acquisition integration: Waters could face unforeseen expenses, lost customers, staff departures or difficulties combining manufacturing, logistics and information systems. Failure to integrate the acquired businesses within the expected timeline could hurt future results.
• Debt: The acquisition increased indebtedness. Debt repayment could affect cash flows, while substantial debt may reduce flexibility, increase borrowing costs or require Waters to delay investments.
• Customer spending: Instrument purchases depend on capital budgets and research funding, which can fluctuate. Changes in customer demand can affect results for reasons outside Waters’ control.
• International exposure: Political events, currency movements, regulatory changes, tariffs and trade restrictions can affect overseas operations, costs and supply chains. The company also has manufacturing and subcontracting operations outside the United States.
• Technology and compliance: Cyberattacks or disruptions to Waters’ systems or those of its partners could affect operations. Changes in government regulation or compliance failures could also harm the business.
• China diagnostics: In Q3 2026, the acquired Diagnostic Solutions business faced a China DRG-related growth headwind. Waters expects the headwind to enter the baseline in Q4 2026.

Bottom line

Our reading

Waters combines sales of laboratory equipment with supplies, software and services used after installation; those relationships give it repeat revenue alongside exposure to customers’ equipment budgets (item1, item7). The acquisition adds diagnostics and biosciences, but also makes integration and debt management central to the business (item1, item1a). New products and testing partnerships offer routes to growth, while competition and international demand remain important constraints (item1, call_prepared).